COYA Stock — Coya Therapeutics Inc.: Cash, EV, Pipeline

Share price

$4.89

Market cap

$114.7M

Cash

$43.2M

Enterprise value

$71.5M

Balance sheet

Cash	$43.2M
Debt	$0.0M
Net cash	$43.2M
Enterprise value	$71.5M
Basic shares	23.5M shares
Fully diluted shares	28.3M shares
Fully diluted market cap	$138.5M
Cash per share	$1.84

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading COYA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 26	COYA 302	Phase 2/3	Amyotrophic Lateral Sclerosis (ALS)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

COYA 302

Phase 2 · Active Modality: dual biologic

Target Tregs (IL-2 / CTLA-4)

Partnerships Dr. Reddy's Laboratories: in-licensed abatacept biosimilar (CTLA4-Ig) for COYA 302; $0.4M upfront, up to ~$2.9M pre-approval milestones (first indication) + ~$20M other development/regulatory/sales milestones, low-six-figure per additional indication, single-digit royalties; DRL licensed to commercialize COYA 302 in certain territories.

Indications

Amyotrophic lateral sclerosis (ALS) (Phase 2)
Frontotemporal dementia (FTD) (Stage not disclosed)

Status note Lead asset ('Pipeline in a Product'). ALSTARS Phase 2 RCT in ALS ongoing (NCT07161999). FTD IND approved (milestone owed to DRL). Combination of proprietary low-dose IL-2 (COYA 301) + CTLA4-Ig.

COYA 301

Stage not disclosed · Active Modality: biologic

Aliases low dose IL-2

Target Tregs (IL-2)

Partnerships n/a (licensed to Dr. Reddy's for certain territories as part of the DRL Agreement)

Indications

Neurodegenerative disorders (Stage not disclosed)

Status note Proprietary low-dose interleukin-2; backbone modality of COYA 302 and planned combination family. No standalone trial stated in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	COYA 302
Lead indication	Amyotrophic Lateral Sclerosis (ALS)
Lead phase	Phase 2/3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07161999	Phase 2/3	Recruiting	Sponsor	Coya Therapeutics	—	Amyotrophic Lateral Sclerosis (ALS)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Coya Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	40,900	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

COYA — Coya Therapeutics Inc.